| Protocol | Description | USC Satellite Location |
0C-14-9
Trial Leaders:
Anthony El-Khoueiry
| A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies
Treatment:
Chemotherapy: Systemic
|
|
0C-18-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase I Study of FID-007 in Patients with Advanced Solid Tumors
Treatment:
Chemotherapy: Systemic
|
|
0C-18-21
Trial Leaders:
Diana Hanna
| A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-19-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Treatment:
(No treatments specified) |
|
0C-19-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with Balstilimab (AGEN2034), an Anti-PD1 Monoclonal Antibody, in Participants With Advanced Cancer
Treatment:
Immunotherapy
|
|
0C-20-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
| USC Newport Beach Oncology
|
0C-20-10
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
Treatment:
Other
|
|
0C-20-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies
Treatment:
Other
|
|
0C-20-14
Trial Leaders:
Jorge Nieva
| Tumor-agnostic precision immunooncology and somatic targeting rational for you (TAPISTRY) Phase II Platform trial
Treatment:
Immunotherapy
|
|
0C-20-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Treatment:
Other
|
|
0C-20-19
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Treatment:
Other
|
|
0C-20-22
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-24
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Treatment:
Immunotherapy
|
|
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors
Treatment:
Immunomodulator
|
|
0C-21-20
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-8
Trial Leaders:
Heinz Josef Lenz
| PhI-129 /NCI 10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
Treatment:
Other
|
|
0C-21-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Treatment:
Other
|
|
0C-22-11
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Study of BA3071 in Patients with Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-12
Trial Leaders:
Diana Hanna
| A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of Decoy20 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-15
Trial Leaders:
Jacob Thomas
| A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Treatment:
Immunotherapy
|
|
0C-22-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1B/2, Open-label Study of Q702 in combination with intravenous Pembrolizumab in Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-17
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-Label, First-in-Human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of SAR444200-Based Regimen in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-19
Trial Leaders:
Anthony El-Khoueiry
| First in Human Dose Escalation Study of AU409 in Patients with Advanced Primary Liver Cancers or Advanced Solid Tumor with Liver Predominant Metastatic Disease
Treatment:
Biological Response Modifier
|
|
0C-22-20
Trial Leaders:
Diana Hanna
| A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
|
|
0C-22-5
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-7
Trial Leaders:
Jacob Thomas
| A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes.
Treatment:
Immunomodulator
|
|
0C-22-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Selected Advanced Solid Tumors with Cohort Expansions at the Recommended Phase 2 Dose
Treatment:
Immunotherapy
|
|
0C-23-1
Trial Leaders:
Jacob Thomas
| An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
Treatment:
Immunotherapy
Other
|
|
0C-23-10
Trial Leaders:
Jacob Thomas
| A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
Treatment:
Biological Response Modifier
|
|
0C-23-11
Trial Leaders:
Anthony El-Khoueiry
| Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
Treatment:
Genetic
Immunotherapy
| USC Koreatown
|
0C-23-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-14
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
Other
|
|
0C-23-15
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-16
Trial Leaders:
Jacob Thomas
| A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
Treatment:
Immunotherapy
|
|
0C-23-17
Trial Leaders:
Jacob Thomas
| Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma
Treatment:
Biological Response Modifier
|
|
0C-23-18
Trial Leaders:
Anthony El-Khoueiry
| A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-21
Trial Leaders:
Heinz Josef Lenz
| PhII-227 / NCI 10486: Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
0C-23-24
Trial Leaders:
Heinz Josef Lenz
| Phase I Study of Autologous CD8+ And CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown
|
0C-23-25
Trial Leaders:
Heinz Josef Lenz
| A Phase I/II, First-in-Human, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-26
Trial Leaders:
Jacob Thomas
| A Phase 1 Study of NM32-2668 (Anti-ROR1 / Anti-CD3/ Anti-HSA Tri- Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-23-5
Trial Leaders:
Anthony El-Khoueiry
| A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
Treatment:
Chemotherapy: Local
|
|
0C-23-6
Trial Leaders:
Jacob Thomas
| Phase 1 Clinical Study on the Tolerability of Utidelone Capsules in Patients with Advanced Solid Tumors
Treatment:
Other
|
|
0C-23-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors
Treatment:
Other
|
|
0C-23-8
Trial Leaders:
Syma Iqbal
| A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin18.2+ Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown, USC Newport Beach Oncology
|
0C-23-9
Trial Leaders:
Jacob Thomas
| Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0S-19-6
Trial Leaders:
Jorge Nieva
| A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in
Patients with HPV 16+ Confirmed Cancers
Treatment:
Immunotherapy
Vaccine
|
|
0S-20-1
Trial Leaders:
Gino In
| Short-term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: a Pilot Safety and Feasibility Study
Treatment:
Other
|
|
0S-20-8
Trial Leaders:
Gino In
| An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Treatment:
Other
Vaccine
|
|
0S-22-9
Trial Leaders:
Howard Liebman
| A Study of ABC008 in T-Large Granular Lymphocyte Leukemia (T-LGLL)
Treatment:
Biological Response Modifier
|
|
0S-23-1
Trial Leaders:
Robert Hsu
| NCI 10507/ PhII-225: A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma
Treatment:
Other
|
|
0S-23-3
Trial Leaders:
Robert Hsu
| PhI-138 / NCI 10509: A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
10M-23-2
Trial Leaders:
Gino In
| A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
Treatment:
Immunotherapy
|
|
10M-23-4
Trial Leaders:
Gino In
| A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants with Unresectable or Metastatic Melanoma Resistant to Checkpoint Inhibitors and After BRAF-MEK Targeting Therapy in Participants with BRAF Mutated Melanoma
Treatment:
Autologous Bone Marrow Transplant
Other
|
|
10M-24-2
Trial Leaders:
Gino In
| NCI 10614 / PhII-239: A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers
Treatment:
Biological Response Modifier
Chemotherapy: Systemic
Immunotherapy
| USC Koreatown
|
11S-22-1
Trial Leaders:
James Hu
| PhII-224 / 10504: A Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
Treatment:
Immunotherapy
| USC Koreatown
|
13NHL-22-3
Trial Leaders:
George Yaghmour
| The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects with Relapsed or Refractory CD19-Positive B-Cell Malignancies
Treatment:
Immunotherapy
|
|
13NHL-23-1
Trial Leaders:
Ann Mohrbacher
| A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for Intravenous Infusion
Treatment:
Biological Response Modifier
Chemotherapy: Systemic
|
|
13NHL-23-3
Trial Leaders:
Ann Mohrbacher
| A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)
Treatment:
Chemotherapy: Local
|
|
13NHL-23-4
Trial Leaders:
Ann Mohrbacher
| A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
Treatment:
Biological Response Modifier
Immunotherapy
|
|
14SK-19-1
Trial Leaders:
Gino In
| Evaluating the PD-1 checkpoint inhibitor, Cemiplimab, as neoadjuvant therapy in high risk localized, locally recurrent, and regionally advanced cutaneous squamous cell carcinoma: a Phase II pilot study
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
14SK-20-1
Trial Leaders:
Gino In
| A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma study
Treatment:
Immunotherapy
| USC Newport Beach Oncology
|
14SK-22-1
Trial Leaders:
Gino In
| BCA101X1101: First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
14SK-24-1
Trial Leaders:
Gino In
| NCI 10592 / PhII-240: A Randomized Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX Trial
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
16M-23-1
Trial Leaders:
Ann Mohrbacher
| Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Treatment:
Other
|
|
1B-10-3
Trial Leaders:
Evanthia Roussos torres
| Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.
Treatment:
Chemotherapy: Systemic
|
|
1B-21-1
Trial Leaders:
Evanthia Roussos torres
| A Randomized, Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Estrogen Receptor Positive, HER2 Negative Breast Cancer (DARE)
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
1B-21-3
Trial Leaders:
Priya Jayachandran
| A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd
Treatment:
Other
| USC Newport Beach Oncology
|
1B-21-8
Trial Leaders:
Danielle Sterrenberg
| A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
1B-22-2
Trial Leaders:
Fumito Ito
| A Phase I Study of In Situ Immunomodulation with CDX-301, Radiotherapy, CDX-1140 and Poly-ICLC in Patients with Unresectable and Metastatic Solid Tumors with Injectable Palpable Disease
Treatment:
Immunotherapy
Radiation: External
|
|
1B-22-3
Trial Leaders:
Priya Jayachandran
| A Dose Finding Phase 1 of Sarilumab plus Capecitabine in HER2/neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab plus Capecitabine in Stage I-III Triple Negative Breast Cancer with High-Risk Residual Disease (EMPOWER)
Treatment:
Chemotherapy: Systemic
|
|
1B-23-3
Trial Leaders:
Daphne Stewart
| A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
1B-23-4
Trial Leaders:
Daphne Stewart
| A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
1B-23-5
Trial Leaders:
Daphne Stewart
| An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07220060 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Participants Over 18 Years of Age with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
Treatment:
Biological Response Modifier
Other
|
|
2N-20-6
Trial Leaders:
Jorge Nieva
| An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Treatment:
Biological Response Modifier
|
|
2N-21-5
Trial Leaders:
Jorge Nieva
| PhI-113/NCI 10327: A Phase 1 Trial of MLN0128 (sapanisertib) and Telaglenastat CB-839) HCl iin Advanced NSCLC Patients
Treatment:
Chemotherapy: Systemic
| USC Koreatown
|
2N-21-6
Trial Leaders:
Jorge Nieva
| A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on or are Intolerant to a PD-1/L-1, EGFR, or ALK Inhibitor
Treatment:
Immunotherapy
Other
| USC Newport Beach Oncology
|
2N-21-9
Trial Leaders:
Jorge Nieva
| A phase II study of subcutaneous atezolizumab in NSCLC patients using a decentralized clinical trial model
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
2N-22-1
Trial Leaders:
Jorge Nieva
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Treatment:
Other
| USC Koreatown, USC Newport Beach Oncology
|
2N-23-3
Trial Leaders:
Robert Hsu
| A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)
Treatment:
Chemotherapy: Systemic
Other
| USC Koreatown, USC Newport Beach Oncology
|
2N-23-4
Trial Leaders:
Jason Ye
| Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies
Treatment:
Immunotherapy
Radiation: External
|
|
2N-23-5
Trial Leaders:
Robert Hsu
| A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer (HARMONi-3)
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
2N-23-6
Trial Leaders:
Robert Hsu
| Phase 2 Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors (TKIs)
Treatment:
Chemotherapy: Systemic
Other
|
|
2N-24-1
Trial Leaders:
Jorge Nieva
| A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
Treatment:
Other
| USC Koreatown, USC Newport Beach Oncology
|
2O-22-1
Trial Leaders:
Jorge Nieva
| A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
2O-22-3
Trial Leaders:
Jorge Nieva
| PhI-135/ NCI 10445: Phase 1 Dose Escalation and Expansion Study of Tazemetostat in Combination of Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Treatment:
Chemotherapy: Systemic
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
2O-23-1
Trial Leaders:
Robert Hsu
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Treatment:
Other
| USC Koreatown, USC Newport Beach Oncology
|
3BD-23-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen
Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic
| USC Newport Beach Oncology
|
3BD-23-2
Trial Leaders:
Anthony El-Khoueiry
| Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Treatment:
Other
|
|
3C-20-6
Trial Leaders:
Heinz Josef Lenz
| An open-label, multicenter, randomized phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAFV600E-mutant colorectal cancer
Treatment:
Chemotherapy: Local
|
|
3C-22-2
Trial Leaders:
Heinz Josef Lenz
| A Phase 2, Randomized, Open-Label Study of Encorafenib and Cetuximab Plus Pembrolizumab Versus Pembrolizumab Alone In Participants with Previously Untreated BRAF V600e-Mutant, MSI-H/DMMR Metastatic Colorectal Cancer (SEAMARK)
Treatment:
Chemotherapy: Local
Chemotherapy: Systemic
|
|
3C-23-1
Trial Leaders:
Heinz Josef Lenz
| An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
3C-23-10
Trial Leaders:
Heinz Josef Lenz
| A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for the First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
Treatment:
Chemotherapy: Systemic
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
3C-23-5
Trial Leaders:
Heinz Josef Lenz
| An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer.
Treatment:
Chemotherapy: Systemic
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
3C-23-6
Trial Leaders:
Sandra Algaze
| A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Treatment:
Immunotherapy
Vaccine
| USC Newport Beach Oncology
|
3C-23-8
Trial Leaders:
Heinz Josef Lenz
| An Open-Label, Multicenter, Phase 1a/1b Study of IGM-8444 as a Single Agent and in Combination in Subjects with Relapsed, Refractory, or Newly Diagnosed Cancers
Treatment:
Anti-Angiogenesis
Biological Response Modifier
Chemotherapy: Systemic
|
|
3C-23-9
Trial Leaders:
Heinz Josef Lenz
| A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer
Treatment:
Other
| USC Newport Beach Oncology
|
3G-20-2
Trial Leaders:
Syma Iqbal
| A Randomized Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) study
Treatment:
Chemotherapy: Local
|
|
3G-21-1
Trial Leaders:
Syma Iqbal
| Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study
Treatment:
Chemotherapy: Systemic
|
|
3G-21-2
Trial Leaders:
Syma Iqbal
| An Open-Label, International, Multicenter, Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with Xelox (Capecitabine and Oxaliplatin) or Irinotecan in Patients with Advanced Gastric Cancer
Treatment:
Chemotherapy: Systemic
|
|
3G-22-1
Trial Leaders:
Syma Iqbal
| A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients with Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
3G-22-3
Trial Leaders:
Syma Iqbal
| A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
3L-23-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Treatment:
Immunotherapy
|
|
3L-23-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)
Treatment:
Biological Response Modifier
Immunotherapy
|
|
3L-23-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, with or without Tiragolumab, in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
3L-23-4
Trial Leaders:
Anthony El-Khoueiry
| A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
3P-23-1
Trial Leaders:
Diana Hanna
| A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine with or without Botensilimab (AGEN1811) in Patients with Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
3P-23-3
Trial Leaders:
Heinz Josef Lenz
| A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
Treatment:
Immunotherapy
Vaccine
|
|
3P-23-5
Trial Leaders:
Steven Grossman
| Pancreatectomy with Arterial Resection Outcomes in Locally Advanced Pancreatic Cancer involving visceral arteries Treated wIth neoadjuVant chemotherapy
Treatment:
Surgery
|
|
3P-23-6
Trial Leaders:
Diana Hanna
| A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
Treatment:
Vaccine
| USC Koreatown, USC Newport Beach Oncology
|
4B-15-11
Trial Leaders:
Sarmad Sadeghi
| A Phase II Trial of sEphB4-HSA in Combination with Anti PD1 Antibody (Pembrolizumab, MK-3475) for Solid Tumors
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
4B-21-1
Trial Leaders:
Siamak Daneshmand
| A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination with Cetrelimab Versus Concurrent Chemoradiotherapy in Participants with Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy
Treatment:
Chemotherapy: Local
Chemotherapy: Systemic
Radiation: Other
|
|
4B-21-3
Trial Leaders:
Hooman Djaladat
| Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of Tookad (padeliporfin) Vascular Targeted Photdynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer.
Treatment:
Chemotherapy: Local
Other
|
|
4B-21-5
Trial Leaders:
Inderbir Gill
| Robotic vascularized composite bladder allograft transplantation: a Phase 0 (first-in-human), single institutional study for deceased donor bladder transplantation
Treatment:
Other
|
|
4B-22-2
Trial Leaders:
Anne Schuckman
| A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment
Treatment:
Immunotherapy
|
|
4B-22-3
Trial Leaders:
Anishka D'Souza
| PhI-133/NCI 10483: Phase Ib trial of Erdafitinib combined with Enfortumab Vedotin following platinum and PD1/L1 inhibitors for metastatic urothelial carcinoma with FGFR2/3 genetic alterations
Treatment:
Immunotherapy
|
|
4B-22-4
Trial Leaders:
Siamak Daneshmand
| A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Treatment:
Immunotherapy
|
|
4B-22-5
Trial Leaders:
Siamak Daneshmand
| Phase I Study of Erdafitinib Intravesical Delivery (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
Treatment:
Chemotherapy: Local
|
|
4B-23-1
Trial Leaders:
Siamak Daneshmand
| ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States [ABLE-41]
Treatment:
Other
|
|
4K-23-1
Trial Leaders:
Monish Aron
| The HistoSonics Edison System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Treatment:
Surgery
|
|
4P-18-2
Trial Leaders:
Monish Aron
| SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 multi-institution randomized prospective clinical trial evaluating the impact of cytoreductive radical prostatectomy combined with best systemic therapy on oncologic and quality of life outcomes in men with newly diagnosed metastatic prostate cancer
Treatment:
Chemotherapy: Systemic
Hormone
Surgery
|
|
4P-21-2
Trial Leaders:
Mike Nguyen
| Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy
Treatment:
Immunotherapy
|
|
4P-23-1
Trial Leaders:
Andre Abreu
| PRAMA (Prostate Resection After Microwave Ablation) MRI/Ultrasound fusion guided Transperineal Targeted Microwave Ablation for Prostate Cancer
Treatment:
Surgery
|
|
4P-23-5
Trial Leaders:
Andre Abreu
| Prospective, Multicenter, Single-Arm Study of Vanquish Water Vapor Ablation for Prostate Cancer
Treatment:
Surgery
|
|
4P-23-6
Trial Leaders:
Jacek Pinski
| PhII-234 / NCI 10487: A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation
Treatment:
Chemotherapy: Systemic
|
|
4P-23-9
Trial Leaders:
Mihir Desai
| Prostate Cancer Treatment with the AquaBeam Robotic System
Treatment:
Surgery
|
|
5GYN-23-2
Trial Leaders:
Koji Matsuo
| A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Treatment:
Chemotherapy: Systemic
Other
|
|
6G-15-2
Trial Leaders:
Frances Chow
| An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or IV Gliomas with IDH1 Mutation
Treatment:
Other
|
|
6G-22-2
Trial Leaders:
Eric Chang
| Feasibility Study of Resection and Gammatile® Followed By Concomitant External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ in Newly Diagnosed Glioblastoma (GBM)
Treatment:
Chemotherapy: Systemic
Radiation: External
Radiation: Other
Surgery
|
|
6G-23-1
Trial Leaders:
David Tran
| Multi-Center Randomized Controlled Phase 2b Clinical Trial to Evaluate the Safety and Efficacy of TVI-Brain-1 Combined with Conformal Radiotherapy and Temozolomide Compared to Standard Therapy as a Treatment for Newly Diagnosed O6-Methylguanine Methyltransferase Negative (MGMT Unmethylated) Grade 4 Astrocytoma (Glioblastoma Multiforme; GBM)
Treatment:
Chemotherapy: Systemic
Immunotherapy
Radiation: External
|
|
6M-22-1
Trial Leaders:
Frances Chow
| An Open-Label, Phase 2 Study of Neo100 in Participants with Residual, Progressive or Recurrent High-Grade Meningioma
Treatment:
Chemotherapy: Local
|
|
7H-21-2
Trial Leaders:
Jacob Thomas
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving Concurrent Chemoradiotherapy for Previously Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Treatment:
Other
|
|
7H-22-2
Trial Leaders:
Mark Swanson
| A Phase II Open Label, Single Arm Study to Evaluate the Efficacy of Pembrolizumab for Leukoplakia
Treatment:
Immunotherapy
|
|
7H-22-3
Trial Leaders:
Jacob Thomas
| PhII-216 /10496: A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
7H-23-1
Trial Leaders:
Jacob Thomas
| PhII-232 /NCI 10553: A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
Treatment:
Other
|
|
7H-23-5
Trial Leaders:
Jacob Thomas
| A Window of Opportunity Study of Taxanes in Head and Neck Cancer
Treatment:
Other
|
|
9L-17-13
Trial Leaders:
Kevin Kelly
| PhI-92: (NCI 10075) A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine and Venetoclax in Acute Myeloid Leukemia
Treatment:
Chemotherapy: Systemic
|
|
9L-18-9
Trial Leaders:
George Yaghmour
| A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
Treatment:
Chemotherapy: Systemic
|
|
9L-21-7
Trial Leaders:
Casey O'Connell
| A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT-MDS-1)
Treatment:
Biological Response Modifier
|
|
9L-22-1
Trial Leaders:
Abdullah Ladha
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Treatment:
Biological Response Modifier
Immunotherapy
|
|
9L-22-2
Trial Leaders:
Caitlin O'Neill
| A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
Treatment:
Biological Response Modifier
|
|
9L-22-3
Trial Leaders:
George Yaghmour
| A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Treatment:
Other
|
|
9L-22-5
Trial Leaders:
Casey O'Connell
| A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
Treatment:
Other
|
|
9L-23-1
Trial Leaders:
Casey O'Connell
| A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)
Treatment:
Other
|
|
9L-23-4
Trial Leaders:
George Yaghmour
| Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Treatment:
Biological Response Modifier
|
|
9L-23-5
Trial Leaders:
George Yaghmour
| A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
Treatment:
Biological Response Modifier
Chemotherapy: Systemic
|
|
9L-23-6
Trial Leaders:
Casey O'Connell
| Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Treatment:
Biological Response Modifier
Immunotherapy
|
|
9L-23-8
Trial Leaders:
Abdullah Ladha
| NCI 10538/ PhII-233: Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
Treatment:
Chemotherapy: Systemic
|
|
CTSU-A011801
Trial Leaders:
Priya Jayachandran
| The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Treatment:
Other
| USC Koreatown, USC Newport Beach Oncology
|
CTSU-A022104
Trial Leaders:
Diane Ling
| The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
Treatment:
Chemotherapy: Systemic
Radiation: External
| USC Koreatown
|
CTSU-A031702
Trial Leaders:
Anishka D'Souza
| A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Treatment:
Chemotherapy: Systemic
Immunotherapy
| USC Newport Beach Oncology
|
CTSU-A091903
Trial Leaders:
Gino In
| A Randomized Double Blind Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
CTSU-A092105
Trial Leaders:
Jacob Thomas
| A092105: Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
CTSU-A211801
Trial Leaders:
Darcy Spicer
| BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation
Treatment:
Immunotherapy
|
|
CTSU-AGCT1532
Trial Leaders:
Anishka D'Souza
| A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors
Treatment:
Chemotherapy: Systemic
| USC Newport Beach Oncology
|
CTSU-CCTG MA.39
Trial Leaders:
Jason Ye
| A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Treatment:
Radiation: External
|
|
CTSU-EA2176
Trial Leaders:
Syma Iqbal
| A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
Treatment:
Chemotherapy: Systemic
| USC Koreatown
|
CTSU-EA8134
Trial Leaders:
Anne Schuckman
| InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study): InPACT-neoadjuvant
Treatment:
Chemotherapy: Systemic
Surgery
|
|
CTSU-EA8212
Trial Leaders:
Siamak Daneshmand
| A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Treatment:
Chemotherapy: Local
Other
|
|
NRG-BN003
Trial Leaders:
Eric Chang
| Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Treatment:
Other
|
|
NRG-BN010
Trial Leaders:
Frances Chow
| A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Treatment:
Immunotherapy
Radiation: Other
Surgery
|
|
NRG-BR007
Trial Leaders:
Diane Ling
| A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Treatment:
Hormone
Radiation: External
|
|
NRG-BR008
Trial Leaders:
Jason Ye
| A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*)
Treatment:
(No treatments specified) |
|
NRG-CC009
Trial Leaders:
Jason Ye
| Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer
Treatment:
Radiation: External
|
|
NRG-GI008
Trial Leaders:
Sandra Algaze
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
NRG-GU008
Trial Leaders:
Lauren Lukas
| Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
Treatment:
Hormone
|
|
NRG-GU010
Trial Leaders:
Lauren Lukas
| Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Treatment:
Radiation: External
|
|
NRG-GU011
Trial Leaders:
Lauren Lukas
| A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
Treatment:
Hormone
Radiation: External
|
|
NRG-HN011
Trial Leaders:
Jacob Thomas
| NRG-HN011: A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
Treatment:
Chemotherapy: Systemic
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
NRG-LU008
Trial Leaders:
Jason Ye
| Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Treatment:
Radiation: External
|
|
SWOG-S1802
Trial Leaders:
Siamak Daneshmand
| Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Treatment:
Chemotherapy: Systemic
Hormone
|
|
SWOG-S1827
Trial Leaders:
Jason Ye
| MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Treatment:
Radiation: External
|
|
SWOG-S1914
Trial Leaders:
Jason Ye
| A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
Treatment:
Chemotherapy: Systemic
Radiation: External
|
|
SWOG-S1931
Trial Leaders:
Varsha Tulpule
| Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Treatment:
Chemotherapy: Systemic
Immunotherapy
Surgery
| USC Koreatown, USC Newport Beach Oncology
|
SWOG-S1937
Trial Leaders:
Sarmad Sadeghi
| A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
SWOG-S2104
Trial Leaders:
Syma Iqbal
| Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
| Protocol | Description | USC Satellite Location |
0C-14-9
Trial Leaders:
Anthony El-Khoueiry
| A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies
Treatment:
Chemotherapy: Systemic
|
|
0C-18-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase I Study of FID-007 in Patients with Advanced Solid Tumors
Treatment:
Chemotherapy: Systemic
|
|
0C-18-21
Trial Leaders:
Diana Hanna
| A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-19-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Treatment:
(No treatments specified) |
|
0C-19-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with Balstilimab (AGEN2034), an Anti-PD1 Monoclonal Antibody, in Participants With Advanced Cancer
Treatment:
Immunotherapy
|
|
0C-20-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
| USC Newport Beach Oncology
|
0C-20-10
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
Treatment:
Other
|
|
0C-20-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies
Treatment:
Other
|
|
0C-20-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Treatment:
Other
|
|
0C-20-19
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Treatment:
Other
|
|
0C-20-22
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-24
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Treatment:
Immunotherapy
|
|
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors
Treatment:
Immunomodulator
|
|
0C-21-20
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-8
Trial Leaders:
Heinz Josef Lenz
| PhI-129 /NCI 10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
Treatment:
Other
|
|
0C-21-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Treatment:
Other
|
|
0C-22-11
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Study of BA3071 in Patients with Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-12
Trial Leaders:
Diana Hanna
| A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of Decoy20 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-15
Trial Leaders:
Jacob Thomas
| A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Treatment:
Immunotherapy
|
|
0C-22-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1B/2, Open-label Study of Q702 in combination with intravenous Pembrolizumab in Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-17
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-Label, First-in-Human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of SAR444200-Based Regimen in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-19
Trial Leaders:
Anthony El-Khoueiry
| First in Human Dose Escalation Study of AU409 in Patients with Advanced Primary Liver Cancers or Advanced Solid Tumor with Liver Predominant Metastatic Disease
Treatment:
Biological Response Modifier
|
|
0C-22-20
Trial Leaders:
Diana Hanna
| A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
|
|
0C-22-5
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Selected Advanced Solid Tumors with Cohort Expansions at the Recommended Phase 2 Dose
Treatment:
Immunotherapy
|
|
0C-23-1
Trial Leaders:
Jacob Thomas
| An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
Treatment:
Immunotherapy
Other
|
|
0C-23-10
Trial Leaders:
Jacob Thomas
| A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
Treatment:
Biological Response Modifier
|
|
0C-23-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-14
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
Other
|
|
0C-23-15
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-17
Trial Leaders:
Jacob Thomas
| Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma
Treatment:
Biological Response Modifier
|
|
0C-23-18
Trial Leaders:
Anthony El-Khoueiry
| A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-24
Trial Leaders:
Heinz Josef Lenz
| Phase I Study of Autologous CD8+ And CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown
|
0C-23-25
Trial Leaders:
Heinz Josef Lenz
| A Phase I/II, First-in-Human, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-26
Trial Leaders:
Jacob Thomas
| A Phase 1 Study of NM32-2668 (Anti-ROR1 / Anti-CD3/ Anti-HSA Tri- Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-23-5
Trial Leaders:
Anthony El-Khoueiry
| A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
Treatment:
Chemotherapy: Local
|
|
0C-23-6
Trial Leaders:
Jacob Thomas
| Phase 1 Clinical Study on the Tolerability of Utidelone Capsules in Patients with Advanced Solid Tumors
Treatment:
Other
|
|
0C-23-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors
Treatment:
Other
|
|
0C-23-8
Trial Leaders:
Syma Iqbal
| A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin18.2+ Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown, USC Newport Beach Oncology
|
0C-23-9
Trial Leaders:
Jacob Thomas
| Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0S-23-3
Trial Leaders:
Robert Hsu
| PhI-138 / NCI 10509: A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
